# Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

> **NCT03138356** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 126 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
- **DRUG:** 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
- **DRUG:** 5 mg dapagliflozin / 850 mg metformin XR FDC
- **DRUG:** 5 mg dapagliflozin / 1000 mg metformin XR FDC
- **DRUG:** 2.5 mg ONGLYZA® (saxagliptin) tablet
- **DRUG:** 5 mg Forxiga® (dapagliflozin) tablet
- **DRUG:** 500 mg Glucophage XR®

## Key facts

- **NCT ID:** NCT03138356
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2017-11-28
- **Final completion:** 2017-11-28
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138356, "Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03138356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*